Literature DB >> 10211326

The effect of reduction of door-to-needle times on the administration of thrombolytic therapy for acute myocardial infarction.

A D Kelion1, A P Banning, M Shahi, J A Bell.   

Abstract

Optimal management of acute myocardial infarction requires rapid administration of thrombolytic therapy. However, only patients who fulfill the following specific criteria are likely to benefit from this treatment: admission within 12 hours of the onset of symptoms, no contraindications, ST elevation or possible new-onset left bundle branch block on the admission electrocardiogram. We employed an aggressive policy to reduce the delay between admission to hospital and the administration of thrombolysis (the 'door-to-needle time'), and investigated whether this approach affected the accuracy of administration of thrombolysis. Patients admitted to the cardiac care unit with acute myocardial infarction, or who were thrombolysed, were identified retrospectively over two equivalent 4-month periods before and after implementation of our policy. Patients were considered eligible for thrombolysis if they fulfilled the criteria mentioned above. The mean (SD) door-to-needle time for all patients who received thrombolysis on admission decreased from 61(70) to 19(20) minutes (p = 0.0004). The proportion of patients eligible for thrombolysis who received treatment increased from 24/38 to 30/30 (p = 0.0002). However, the proportion of patients receiving thrombolysis who did not fulfill our criteria also increased, from 3/27 to 11/41 (p = 0.1). There were no complications of thrombolysis in the first study period, but two cerebrovascular accidents in the second period; both patients fulfiled our criteria for treatment. We conclude that simple educational measures greatly reduced door-to-needle times and led to a higher proportion of eligible patients receiving thrombolysis. However, greater pressure on medical staff to make rapid management decisions increased the proportion of patients being thrombolysed inappropriately.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10211326      PMCID: PMC2361058          DOI: 10.1136/pgmj.74.875.533

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  Thrombolytic therapy for elderly patients.

Authors:  E J Topol; R M Califf
Journal:  N Engl J Med       Date:  1992-07-02       Impact factor: 91.245

2.  Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy.

Authors:  D R Cragg; H Z Friedman; J D Bonema; I A Jaiyesimi; R G Ramos; G C Timmis; W W O'Neill; T L Schreiber
Journal:  Ann Intern Med       Date:  1991-08-01       Impact factor: 25.391

3.  Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction.

Authors:  J K French; B F Williams; H H Hart; S Wyatt; J E Poole; C Ingram; C J Ellis; M G Williams; H D White
Journal:  BMJ       Date:  1996-06-29

4.  Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT).

Authors:  J Rawles
Journal:  J Am Coll Cardiol       Date:  1994-01       Impact factor: 24.094

5.  Patients with suspected myocardial infarction who present with ST depression.

Authors:  H S Lee; S J Cross; J M Rawles; K P Jennings
Journal:  Lancet       Date:  1993-11-13       Impact factor: 79.321

  5 in total
  2 in total

Review 1.  A review of interventions and system changes to improve time to reperfusion for ST-segment elevation myocardial infarction.

Authors:  Kelly A McDermott; Christian D Helfrich; Anne E Sales; John S Rumsfeld; P Michael Ho; Stephan D Fihn
Journal:  J Gen Intern Med       Date:  2008-05-06       Impact factor: 5.128

2.  Effective Factors in Door-to-Needle Time for Streptokinase Administration in Patients With Acute Myocardial Infarction Admitted to the Emergency Department.

Authors:  Ali Omraninava; Amir Masoud Hashemian; Babak Masoumi
Journal:  Trauma Mon       Date:  2016-02-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.